Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan) and Cozaar® (Losartan) in Adult Patients With Grade I-II Arterial Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 179 participants.

Also called NCT02248961

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 179 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02248961
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02248961. Randomized; no masking; primary purpose treatment. Start 2014-05 (registry gives no type); primary completion 2015-08 (actual). Results posted on 2019-05-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan) and Cozaar® (Losartan) in Adult Patients With Grade I-II Arterial Hypertension
Condition
Arterial Hypertension
Intervention (Drug)
Fimasartan
Intervention (Drug)
Losartan
Lead sponsor
R-Pharm (class: industry)
Collaborator
Covance (class: industry)
Collaborator
Boryung Pharmaceutical Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct02248961
Content hash
063d0008ddb6e14fb8836ad99da480b695b7a6adccdc56a381702241fe67d061